Partner Carl Hittinger and Associate Lesley Grossberg co-authored an article in the April 30, 2015, issue of the New Jersey Law Journal. Titled “Refusals to Deal Still at Issue in ‘Celgene’ Case,” the article analyzes Mylan Pharmaceuticals v. Celgene Corp., pending in the U.S. District Court for the District of New Jersey, in which Mylan is alleging that Celgene’s refusal to provide it samples of two drugs it manufactures and sells amounts to unlawful monopolization under Section 2 of the Sherman Antitrust Act.
Read the article.